News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical (GMED) has been in focus after a recent upgrade to Zacks Rank #1, which came shortly after the company reaffirmed its …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Globus Medical (GMED) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Globus Medical (GMED) has seen positive momentum with a 7.39% 90-day share price return following an earnings beat and higher EPS outlook. Despite a year-to-date dip, its 1-year total shareholder return is 40.41%. A valuation narrative suggests the stock is 23.3% undervalued, with a …
Globus Medical (GMED) reported a strong Q2 2026 with record non-GAAP earnings per share and a high adjusted EBITDA margin, indicating significant margin strength. Despite these gains, the company faces challenges with Nevro sales declining and robotics adoption being slower than anticipated, leading to …
Key Points Interested in Globus Medical, Inc.? Here are five stocks we like better. Q2 revenue rose 6% to $789.6 million, while record non-GAAP EPS increased 56% to $1.34 and adjusted EBITDA margin expanded to 35.4%. Spine and trauma growth offset declines in enabling …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Globus Medical (GMED) recently reported Q2 2026 results showing increased revenue but decreased net income and diluted EPS, indicating margin compression. While the company reaffirmed its full-year revenue outlook, the focus has shifted to cost control and integration of acquisitions to improve profitability. The …
Globus Medical, Inc. GMED used its second-quarter 2026 call to emphasize margin execution and continued spine share gains, while management flagged Nevro and Enabling Technologies as risks within the second-half outlook. GMED's second-quarter Non-GAAP EPS of $1.34 beat the $1.12 Zacks Consensus Estimate. Revenues …
Globus Medical (NYSE:GMED) Beats Q2 CY2026 Sales Expectations Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q2 CY2026, with sales up 5.9% year on year to $789.6 million. The company expects the full year's revenue to be around $3.2 billion, close to …
Globus Medical (NYSE: GMED) announced strong second-quarter 2026 results, with worldwide net sales increasing by 5.9% to $789.6 million and non-GAAP diluted EPS rising 55.8% to $1.34. The company reaffirmed its 2026 revenue guidance of $3.18–$3.22 billion but raised its non-GAAP fully diluted EPS …
For the quarter ended June 2026, Globus Medical (GMED) reported revenue of $789.61 million, up 5.9% over the same period last year. EPS came in at $1.34, compared to $0.86 in the year-ago quarter. The reported revenue represents a surprise of +0.35% over the …
Globus Medical AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second Quarter 2026: Worldwide net sales were $789.6 million, an increase …
As the second-quarter earnings season progresses, this week marks an important period for many medical-sector companies. Per the latest Earnings Preview report, the Medical sector's earnings might have suffered due to a dull macroeconomic scenario, including policy uncertainty, cost inflation and tariff-related impacts. However, …
Wall Street analysts expect Globus Medical (GMED) to post quarterly earnings of $1.12 per share in its upcoming report, which indicates a year-over-year increase of 30.2%. Revenues are expected to be $786.86 million, up 5.6% from the year-ago quarter. Over the past 30 days, …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Globus Medical (GMED) stock has seen renewed attention following a 7.84% gain over the last seven days, despite declines over the past 30 and 90 days. While the company's 1-year total shareholder return is positive at 52.33%, investors are debating whether the recent rebound …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Globus Medical GMED is scheduled to report second-quarter 2026 results on Aug. 6, after market closes. In the last reported quarter, the company's adjusted earnings per share (EPS) of $1.12 beat the Zacks Consensus Estimate by 21.74%. Globus Medical's earnings topped estimates in each …
Globus Medical (GMED) stock has seen a significant return of 49.1% over the past year, yet current valuations suggest it may still be undervalued, particularly when considering its P/E ratio compared to the Medical Equipment industry and its peers. The company's tailored fair P/E …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Globus Medical stock has delivered a strong 52.3% return over the past year, and the key issue now is whether that share price …
Globus Medical director David D. Davidar reported a bona fide gift of 2,500 Class A Common Stock shares on July 27, 2026. This transaction was not part of a Rule 10b5-1 trading plan. Following the gift, Davidar directly holds 507,675 shares and indirectly owns …
Globus Medical Director David Davidar transferred 2,500 shares of Class A Common Stock on July 27, 2026, as disclosed in a regulatory filing. This non-sale transaction reduced his direct beneficial ownership while his indirect holdings through a family trust remained significant. The disclosure offers …
Kuehn Law, PLLC is investigating whether officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term GMED stockholders to contact them to explore potential damages and corporate governance reforms, emphasizing that …
Globus Medical Inc Class A generated €2.50 billion in revenue last year, with its Musculoskeletal Solutions segment contributing the most at €2.38 billion. The majority of this revenue, €2.02 billion, came from the United States. This indicates a strong focus and performance in musculoskeletal …
Globus Medical, Inc. GMED is gaining market share in the musculoskeletal solutions space, banking on the strong performance of its implantable devices, biologics, accessories and unique surgical instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures. A solid financial health also …
Sharemaestro market context Price below Trend Line 52 weeks +40.2% · Next-week setup negative 10.2%Search by ticker symbol or company name and select a result to open its chart.